Dr. Daud on the Combinations of Immunotherapy for Melanoma

Adil Daud, MD
Published: Thursday, Jul 06, 2017



Adil Daud, MD, a clinical professor, Department of Medicine at University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses potential combinations of immunotherapy for the treatment of patients with melanoma.

LAG-3 is being looked at in combination with PD-1, which has shown response in patients who had progressed previously on a PD-1 inhibitor, explains Daud.

Additionally, there are some interesting 4-1BB antibodies that appear to be have some activity when combined. More biomarker research is needed to determine which combination will benefit patients, states Daud.
 


Adil Daud, MD, a clinical professor, Department of Medicine at University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses potential combinations of immunotherapy for the treatment of patients with melanoma.

LAG-3 is being looked at in combination with PD-1, which has shown response in patients who had progressed previously on a PD-1 inhibitor, explains Daud.

Additionally, there are some interesting 4-1BB antibodies that appear to be have some activity when combined. More biomarker research is needed to determine which combination will benefit patients, states Daud.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: 13th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 28, 20182.0
Publication Bottom Border
Border Publication
x